Elimination and organ distribution of intravenously administered allogeneic and xenogeneic IgG modifications. (Standard IgG, F (ab)2-fragments and beta-propiolactone treated IgG) in dogs
- PMID: 364571
- DOI: 10.1007/BF01851492
Elimination and organ distribution of intravenously administered allogeneic and xenogeneic IgG modifications. (Standard IgG, F (ab)2-fragments and beta-propiolactone treated IgG) in dogs
Abstract
Dog IgG was produced by fractionation procedures used for the production of clinically used i.v. gammaglobulins. Chemical modification of dog IgG was done by pepsin or beta-propiolactone treatment. The intravascular half-life of beta-propiolactone IgG was 8.5 +/- 2.1 days compared to 4.5 +/- 1.6 days of pepsin treated IgG. Tissue concentrations of radioactive labelled beta-propiolactone IgG were generally higher than of pepsin digested IgG. Pepsin treated Igg was degraded to a significantly higher extent (26% of the administered radioactivity was bound to fragments smaller than 6000 MW after three days) than beta-propiolactone IgG (9% fragments after the same interval, P less than 0.001). It is concluded that the short intravascular half-life of pepsin IgG cannot be explained by increased extravascular filling, but is due to rapid degradation and excretion via the kidneys. There was no obvious difference in elimination and organ distribution between standard and beta-propiolactone IgG.
Similar articles
-
[Concentration of intravenously administered gammaglobulin preparations in dog skin (author's transl)].Arch Dermatol Res (1975). 1977 Dec 27;260(3):201-6. doi: 10.1007/BF00561414. Arch Dermatol Res (1975). 1977. PMID: 74982 German.
-
Enhanced pepsin digestion: a novel process for purifying antibody F(ab')(2) fragments in high yield from serum.J Immunol Methods. 2002 May 1;263(1-2):57-74. doi: 10.1016/s0022-1759(02)00031-5. J Immunol Methods. 2002. PMID: 12009204
-
Kinetics of whole serum and prepurified IgG digestion by pepsin for F(ab')2 manufacture.Biotechnol Prog. 2003 Jul-Aug;19(4):1176-82. doi: 10.1021/bp034037+. Biotechnol Prog. 2003. PMID: 12892479
-
Composition of immune deposits present in glomeruli of NZB/W F1 mice.Clin Immunol Immunopathol. 1991 Dec;61(3):296-308. doi: 10.1016/s0090-1229(05)80002-9. Clin Immunol Immunopathol. 1991. PMID: 1934620
-
Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.Clin Pharmacokinet. 2003;42(8):721-41. doi: 10.2165/00003088-200342080-00002. Clin Pharmacokinet. 2003. PMID: 12846594 Review.
Cited by
-
[Problems of intravenous gammaglobulin therapy (author's transl)].Klin Wochenschr. 1980 Aug 15;58(16):797-809. doi: 10.1007/BF01491100. Klin Wochenschr. 1980. PMID: 6161272 German.
-
Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins.Pharm Res. 2006 Aug;23(8):1743-9. doi: 10.1007/s11095-006-9018-1. Pharm Res. 2006. PMID: 16850270